SG11201605900VA - Treatment of neoplasia - Google Patents

Treatment of neoplasia

Info

Publication number
SG11201605900VA
SG11201605900VA SG11201605900VA SG11201605900VA SG11201605900VA SG 11201605900V A SG11201605900V A SG 11201605900VA SG 11201605900V A SG11201605900V A SG 11201605900VA SG 11201605900V A SG11201605900V A SG 11201605900VA SG 11201605900V A SG11201605900V A SG 11201605900VA
Authority
SG
Singapore
Prior art keywords
neoplasia
treatment
Prior art date
Application number
SG11201605900VA
Other languages
English (en)
Inventor
David Cade
Michael Tapner
Original Assignee
Sirtex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900232A external-priority patent/AU2014900232A0/en
Application filed by Sirtex Medical Ltd filed Critical Sirtex Medical Ltd
Publication of SG11201605900VA publication Critical patent/SG11201605900VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201605900VA 2014-01-24 2015-01-23 Treatment of neoplasia SG11201605900VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014900232A AU2014900232A0 (en) 2014-01-24 Treatment of Neoplasia
PCT/AU2015/000037 WO2015109367A1 (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Publications (1)

Publication Number Publication Date
SG11201605900VA true SG11201605900VA (en) 2016-08-30

Family

ID=53680513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605900VA SG11201605900VA (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Country Status (12)

Country Link
US (1) US10849900B2 (enExample)
EP (1) EP3096752A4 (enExample)
JP (1) JP2017503846A (enExample)
KR (1) KR102317751B1 (enExample)
CN (1) CN106102735A (enExample)
AU (1) AU2015208666B2 (enExample)
BR (1) BR112016016932A8 (enExample)
CA (1) CA2937015C (enExample)
IL (1) IL246880B (enExample)
PH (1) PH12016501407A1 (enExample)
SG (1) SG11201605900VA (enExample)
WO (1) WO2015109367A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107246A1 (en) * 2016-12-16 2018-06-21 The Australian National University Improving selective internal radiation therapy
EP3745979B1 (en) 2018-01-29 2025-11-19 Bard Access Systems, Inc. Connection system for establishing an electrical connection through a drape and methods thereof
WO2019221926A1 (en) 2018-05-18 2019-11-21 Bard Access Systems, Inc. Connection systems and methods thereof for establishing an electrical connection through a drape
EP3968837B1 (en) 2019-05-15 2025-02-26 Boston Scientific Scimed, Inc. Medical device having asymmetric bending
EP3996571A4 (en) 2019-07-12 2023-06-28 Bard Access Systems, Inc. Catheter tracking and placement system including light emitting diode array
CN112336338A (zh) 2019-08-08 2021-02-09 巴德阿克塞斯系统股份有限公司 包括光纤连接器模块的形状感测系统及其方法
EP4355418A1 (en) * 2021-06-14 2024-04-24 Novocure GmbH Methods of treating and preventing cancer with alternating electric fields, radioactive particles, and systemic therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6379648B1 (en) 1999-02-01 2002-04-30 The Curators Of The University Of Missouri Biodegradable glass compositions and methods for radiation therapy
AU2636400A (en) 1999-02-02 2000-08-25 Curators Of The University Of Missouri, The Process for making ceramic microspheres
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
AUPR098200A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Production of low density radionuclide containing microspheres
AU2003903387A0 (en) * 2003-07-02 2003-07-17 Sirtex Medical Limited Combination therapy for treatment of neoplasia
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof

Also Published As

Publication number Publication date
NZ723150A (en) 2021-05-28
CA2937015C (en) 2022-08-02
BR112016016932A8 (pt) 2020-06-16
EP3096752A1 (en) 2016-11-30
AU2015208666A1 (en) 2016-09-01
KR20160122142A (ko) 2016-10-21
KR102317751B1 (ko) 2021-10-27
US20170000795A1 (en) 2017-01-05
CA2937015A1 (en) 2015-07-30
IL246880B (en) 2021-10-31
IL246880A0 (en) 2016-08-31
US10849900B2 (en) 2020-12-01
JP2017503846A (ja) 2017-02-02
EP3096752A4 (en) 2017-10-18
CN106102735A (zh) 2016-11-09
BR112016016932A2 (pt) 2017-08-08
AU2015208666B2 (en) 2019-08-22
PH12016501407A1 (en) 2016-08-31
WO2015109367A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
PL3851537T3 (pl) Leczenie hiperbilirubinemii
GB201701673D0 (en) Methods of well treatment
IL248856B (en) New treatment
SG11201609652RA (en) Treatment of polybacterials infections
GB201410116D0 (en) Method of treatment
IL246880A0 (en) Tumor treatment
SG11201610243YA (en) Treatment of severe hypertriglyceridemia
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201412411D0 (en) Treatment
HK1230493A1 (en) Treatment of neoplasia
AU2014900232A0 (en) Treatment of Neoplasia
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201417465D0 (en) Treatment of cancers
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment
GB201413317D0 (en) Atheroscierosis treatment